Point72 Asia (Singapore)’s Bristol-Myers Squibb BMY Stock Holding History

Point72 Asia (Singapore)’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-81,262	Closed	-$4.6M	–	893
2024 Q4	$4.6M	Buy	81,262 +57,086	+236%	+$3.19M	1.21%	13
2024 Q3	$1.25M	Buy	+24,176	New	+$1.13M	0.24%	78
2024 Q1	–	Sell	-7,224	Closed	-$371K	–	1064
2023 Q4	$371K	Buy	+7,224	New	+$379K	0.09%	95

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asia (Singapore)'s BMY Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 81,262 shares — an estimated $4.6M sold.

Point72 Asia (Singapore) first reported a position in BMY in Q4 2023 and held it in 3 quarters. The position peaked at $4.6M in Q4 2024. 2,485 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

Point72 Asia (Singapore) reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
Point72 Asia (Singapore) sold 81,262 Bristol-Myers Squibb shares in Q1 2025, an estimated $4.6M.
Point72 Asia (Singapore) first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 3 quarters.
Point72 Asia (Singapore)'s Bristol-Myers Squibb position peaked at $4.6M in Q4 2024.
2,485 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.